Invalidity dossier
US 9803000
Human cytomegalovirus neutralizing antibodies and use thereof
Current assignee: Institute for Research in Biomedicine
Added 9/21/2026, 10:31:17 AM
Active provider: DeepSeek · deepseek-flash
Patent summary
Title, assignee, inventors, filing/issue dates, abstract, and a plain-language overview of the claims.
Patent Overview — US9803000B1
Title: Human cytomegalovirus neutralizing antibodies and use thereof
Patent number: US9803000B1 (application US15/637,513)
Assignee: Institute for Research in Biomedicine (IRB); originally assigned to the same. Inventors: Antonio Lanzavecchia and Annalisa Macagno. Assignment recorded 2017-06-29.
Key dates (per the supplied text):
- Prior art date: 2008-07-16 (also listed as the priority date, noted as an assumption)
- Filing date: 2017-06-29
- Publication/grant date: 2017-10-31
- Anticipated expiration: 2029-07-15
- Legal status: Expired – Fee Related
Purpose and plain-language scope: The patent concerns human antibodies that neutralize human cytomegalovirus (CMV), and uses of those antibodies. Classification entries place it in antibody technology against viruses, specifically Cytomegalovirus (C07K16/089), with therapeutic antiviral uses (A61P31/20, A61P31/22) and antibody-containing medicinal preparations (A61K39/42). Classification also indicates human-origin immunoglobulins (C07K2317/21), CDR and variable-region features (C07K2317/565, C07K2317/56), antibody fragments such as Fab, Fab′, F(ab′)2 and scFv (C07K2317/54, /55, /622), and combinations of two or more separate antibodies (A61K2039/507). Prior-art keywords are "antibody," "seq," "antigen binding," "binding fragment," and "antibodies."
Related family members noted in the text include US20170334972A1, US10040845B2, US10414817B2, US10889632B2, and US20210087257A1.
What the excerpt does not establish:
The supplied text is bibliographic and classification data plus a truncated classification list. It contains no claims, no specification, no amino acid or nucleic acid sequences, no epitope definition, no experimental data, and no stated dosage, formulation, or method steps. It also does not establish the specific antigen target beyond CMV, the number or identity of disclosed antibodies, or the exact scope of any claim. No legal conclusions about validity, enforceability, or claim coverage can be drawn from this excerpt.
Source: https://patents.google.com/patent/[US9803000](/patent/US9803000)/en
Generated 10/1/2026, 10:01:33 PM
Cases on file (0)
Specific litigation cases in our database that name US patent 9803000. The free-form analysis below may also discuss cases beyond this list.
No cases on file mention this patent. Upload a CSV or add a case manually in Admin → Manage litigation cases.
Litigation summary
Past and pending lawsuits — plaintiffs, defendants, jurisdictions, outcomes, and notable rulings.
Proceedings on file (0)
All PTAB activity →AIA trial proceedings (IPR / PGR / CBM) filed at the USPTO Patent Trial and Appeal Board against this patent. Sourced from the USPTO Open Data Portal and refreshed every six hours; each proceeding number deep-links to the PTAB E2E docket.
No PTAB proceedings on file. This patent has not been challenged via IPR, PGR, or CBM. The absence is itself a signal — well-asserted patents eventually attract IPRs. The LLM analysis below may surface filings the ODP feed hasn’t indexed yet.
PTAB challenges
AIA trial proceedings at the USPTO Patent Trial and Appeal Board — IPR, PGR, and CBM. Petitioners, judge panels, claim-level invalidation outcomes from Final Written Decisions, and Federal Circuit appeals. The single most important defensive datapoint after litigation history.
Assignment history
Inventors, original assignee, and the chain of ownership recorded with the USPTO — including the correspondent attorney who recorded each assignment, since shell-LLC chains often share one repeat-player attorney even when the entity names look unrelated. Surfaces NPE / patent-troll patterns: shell-entity transfers, known asserters in the chain, repeat correspondent fingerprints, pre-litigation assignments, and bankruptcy fire-sales.
Prior art
Earlier patents, publications, and products that may anticipate or render the claims unpatentable.
Obviousness
Combinations of prior art that suggest the claimed invention would have been obvious under 35 U.S.C. § 103.
Extensions
Patent term adjustments, term extensions, continuations, divisionals, family members, and expiration dates.
Derivative works
Defensive disclosure: derivative variations of each claim designed to render future incremental improvements obvious or non-novel.